SAB Biotherapeutics CFO Michael King resigns effective June 4; Mark Conley appointed Interim CFO

SAB Biotherapeutics, Inc.

CFO Michael King resigns effective June 4, 2024 to become CEO at private oncology company; will remain advisor through year-end.
Mark Conley, current VP Finance, appointed Interim CFO; board launches formal search for permanent replacement.
Conley's compensation unchanged under existing agreement: $303K base salary, bonus eligibility, and 250,000 stock options.
Company confirms FY2024 outlook and upcoming Phase 1 topline data readout for lead candidate SAB-142.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Mark Conley

Interim Chief Financial Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2024-06-04
Filed: May 31, 2024, 7:59 PM ET

On May 30, 2024, Mark Conley, 62, was appointed Interim Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective June 4, 2024.

Departed

Michael King, Jr.

Chief Financial Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2024-06-04
Successor: Mark Conley
Filed: May 31, 2024, 7:59 PM ET

On May 26, 2024, Michael King, Jr., Chief Financial Officer of the Company, informed the Company that he will resign from his position with the Company, effective June 4, 2024, to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Conley was appointed as Interim Chief Financial Officer at SAB Biotherapeutics, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On May 30, 2024, Mark Conley, 62, was appointed Interim Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective June 4, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael King, Jr. resigned as Chief Financial Officer at SAB Biotherapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On May 26, 2024, Michael King, Jr., Chief Financial Officer of the Company, informed the Company that he will resign from his position with the Company, effective June 4, 2024, to pursue another opportunity.

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-066856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.